IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_95
Abstract: decreased lymphoma‐specific mortality, adjusted HR 0.09 (0.01, 0.64). Further dose‐response analyses are planned. Conclusions: In this very large population‐based unselected lymphoma population, statins were not associated with worse outcomes and thus appear safe to use… read more here.
Keywords: pharmacokinetic results; exposure rituximab; ibrutinib increases; increases systemic ... See more keywords